摘要
目的评价依布利特与普罗帕酮转复心房颤动的临床疗效及安全性。方法入选心房颤动患者66例,并随机分为试验组31例和对照组35例。试验组10 min内静脉注射依布利特1 mg,对照组10 min内静脉注射普罗帕酮70mg,2组如未转复成功可于给药结束后再重复给药一次。观察2组患者用药后90 min内窦性心律转复成功率、转复时间及不良反应发生率。结果试验组用药90 min内转复窦性心律的成功率为74.2%,对照组转复成功率为51.4%。试验组中位转复时间为20.5 min,显著低于对照组的25.2 min(P<0.05)。试验组与对照组不良反应发生率分别为29.0%和25.7%,差异无统计学意义(P>0.05)。结论依布利特转复心房颤动成功率较高,转复时间较短。
Objective To evaluate the clinical efficacy and Safety of ibutilide and propafenone in the treatment of patients with atrial fibrilla- tion. Methods A total of 66 patients with atrial fibrillation were included in this study. Of the recruited 66 subjects, 31 cases （experiment group ） received ibutilide 1 mg by intravenous injection within 10 rain and other 35 cases （control group） received propafenone 70 mg by intravenous injection within 10 min. The treatment procedure were done again if the atrial fibrillation still existed after administration. The successful rate and adverse reactions were recorded in the two groups. Results The successful rate was 74.2% in experiment group and 51.4% in control group with statistical difference （P 〈 0.05 ）. The median time of cardioversion was 20. 5 min for experiment group and 25.2 min in control group with significant difference （P 〈 0. 05 ）. The rate of adverse reactions were 29.0% and 25.7% in the treatment and control group, respectively without statistical difference （P 〉 0. 05 ）. Conclusion The successful rate of ibutilide in the treatment of patients with atrial fibrillation is relative higher with short period of time for success.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第15期1475-1476,1493,共3页
The Chinese Journal of Clinical Pharmacology
基金
天津市卫生局医药卫生重点基金资助项目(2011BHKZ005)
